On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
219 Results
Protocol Code |
Study Title |
Active substance/Medical device |
Study Phase |
Therapeutic Area |
S221237-176 |
Comparative pharmacokinetic study of three prolonged release formulations and one immediate release formulation of S221237…
|
S221237
|
Phase 1
|
Neuropsychiatric Diseases
|
|
SPLFIO-174 |
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung…
|
Cemiplimab (anti-PD1 antibody), S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), S095029 (anti-NKG2A antibody)
|
Phase 1-2
|
Cancers
|
|
CL1-95035-001 |
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine…
|
|
Phase 1
|
Cancers
|
|
CL3-95031-007 |
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With…
|
Ivosidenib
|
Phase 3
|
Cancers
|
|
S005190-170 |
Exploratory bioavailability of two formulations of gliclazide MR tablets 120 mg (I.R.I.S.) in healthy volunteers…
|
GLICLAZIDE
|
Phase 1
|
Metabolism
|
|
CL1-ONCO-001 |
An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis…
|
No drug
|
Phase 1
|
Cancers
|
|
AG881-C-004 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or…
|
vorasidenib
|
Phase 3
|
Cancers
|
|
|
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or…
|
vorasidenib
|
Phase 3
|
Cancers
|
|
CL3-06593-018 |
Evaluation of the clinical efficacy and safety of perindopril 5 mg / indapamide 1.25 mg…
|
AMLODIPINE, INDAPAMIDE, PERINDOPRIL
|
Phase 3
|
Cardiovascular Diseases
|
|
SYM021-01 |
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of…
|
Anti-PD-1
|
Phase 1
|
Cancers
|
|
CL1-95012-002 |
An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the…
|
"S095012"
|
Phase 1
|
Cancers
|
|
CL3-LUSEO-001 |
Study assessing the glucose-lowering efficacy and safety of luseogliflozin on top of metformin in Caucasian…
|
Luseogliflozin
|
Phase 3
|
Metabolism
|
|
CL1-95032-005 |
Update in progress A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With… |
S095032
|
Phase 1
|
Cancers
|
|
AG120-C-005 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable…
|
AG120, Ivosidenib
|
Phase 3
|
Cancers
|
|
CL3-05166-003 |
Evaluation of the clinical efficacy and safety of Amlodipine 5mg/ Bisoprolol fumarate 5mg /Perindopril arginine…
|
AMLODIPINE, BISOPROLOL, PERINDOPRIL, S05166
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05179-002 |
Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or…
|
AMLODIPINE, BISOPROLOL, INDAPAMIDE, PERINDOPRIL, S05179
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-95026-001 |
A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to…
|
Futuximab, Modotuximab, S095026
|
Phase 3
|
Cancers
|
|
CL1-95012-001 |
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors
|
Solid tumors
|
Phase 1-2
|
Cancers
|
|
CL1-95029-001 |
A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of…
|
S095029
|
Phase 1
|
Cancers
|
|
AG120-881-C-001 |
A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects…
|
AG-120, AG881
|
Phase 1
|
Cancers
|
|
AG270-C-001 |
A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors…
|
AG-270
|
Phase 1
|
Cancers
|
|
AG120-C-009 |
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in…
|
AG-120, Ivosidenib
|
Phase 3
|
Cancers
|
|
AG120-C-002 |
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…
|
AG-120
|
Phase 1
|
Cancers
|
|
AG120-C-001 |
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…
|
AG-120
|
Phase 1
|
Cancers
|
|
AG120-221-C-001 |
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction…
|
AG-120, AG-221
|
Phase 1
|
Cancers
|
|
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines carried out in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry that contains information on clinical studies of human participants carried out around the world.
SEE MORE
ISRCTN registry
The International Standard Randomized Controlled Trial Number (ISRCTN) registry is a primary clinical trial registry recognised by World Health Organization (WHO) and International Committee of Medical Journal Editor (ICMJE) that accepts all clinical research studies.
SEE MORE